Literature DB >> 2649292

MAC technique (morphology antibody chromosomes) in phenotypic identification of proliferating NK and T cells in interleukin-2-stimulated lymphocyte cultures.

P E Kovanen1, T Timonen, I Seppälä, S Knuutila.   

Abstract

Human peripheral blood lymphocytes were activated with recombinant interleukin 2 (rIL-2) and cultured in fetal calf serum (FCS)- or human-AB-serum-supplemented media. Proliferative cells were identified by the MAC technique (morphology antibody chromosomes) which enables the immunoenzymatic identification of both mitotic and non-proliferating cells in unfractionated lymphocyte populations. The results indicate that the phenotype of more than 90% of proliferative lymphocytes can be characterized by using antibodies against T cells and NK cells. Substantial mitotic activity of CD4-positive (CD4+) T cells was observed only in FCS-supplemented cultures, whereas in serum-free or human-AB-serum-supplemented cultures mostly CD8+ T cells and NK cells proliferated. The proportion of NK cells among all mitotic cells varied between 14 and 32%. Interestingly, in unfractionated cultures approximately 13% NK cells entered mitoses in the presence of rIL-2, suggesting that the poor proliferative capacity of purified NK cells demonstrated previously may be due to the lack of accessory stimulatory signals. The proliferation of B cells was minimal in all experiments. The MAC technique is a useful addition to the techniques by which lymphocyte growth regulation is monitored.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2649292      PMCID: PMC1541964     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  18 in total

1.  Interleukin-2 augments natural killer cell activity.

Authors:  C S Henney; K Kuribayashi; D E Kern; S Gillis
Journal:  Nature       Date:  1981-05-28       Impact factor: 49.962

2.  Characterization of cloned cytotoxic lymphocytes with NK-like activity.

Authors:  H Acha-Orbea; P Groscurth; R Lang; L Stitz; H Hengartner
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

3.  Differentiation of NK-like cells from OKT3-, OKT11+, and OKM1+ small resting lymphocytes by culture with autologous T cell blasts and lymphokine.

Authors:  H S Warren
Journal:  J Immunol       Date:  1984-06       Impact factor: 5.422

4.  Cultures of human natural killer cells (large granular lymphocytes) and T cells in the presence of interleukin-2-containing conditioned medium.

Authors:  T Timonen; J R Ortaldo; B M Vose; M Henkart; J Alvarez; R B Herberman
Journal:  J Reticuloendothel Soc       Date:  1983-01

5.  Clonal chromosomal abnormalities showing multiple-cell-lineage involvement in acute myeloid leukemia.

Authors:  M Keinänen; J D Griffin; C D Bloomfield; J Machnicki; A de la Chapelle
Journal:  N Engl J Med       Date:  1988-05-05       Impact factor: 91.245

6.  Early mitogen-induced metabolic events essential to proliferation of human T lymphocytes: dependence of specific events on the influence of adherent accessory cells.

Authors:  W B Bruszewski; J A Bruszewski; H Tonnu; S L Ferezy; R L O'Brien; J W Parker
Journal:  J Immunol       Date:  1984-06       Impact factor: 5.422

7.  Prerequisite for the induction of lymphokine-activated killer cells from T lymphocytes.

Authors:  H Sawada; T Abo; S Sugawara; K Kumagai
Journal:  J Immunol       Date:  1988-05-15       Impact factor: 5.422

8.  Response of resting human peripheral blood natural killer cells to interleukin 2.

Authors:  G Trinchieri; M Matsumoto-Kobayashi; S C Clark; J Seehra; L London; B Perussia
Journal:  J Exp Med       Date:  1984-10-01       Impact factor: 14.307

9.  Transient expression of interleukin 2 receptors. Consequences for T cell growth.

Authors:  D A Cantrell; K A Smith
Journal:  J Exp Med       Date:  1983-12-01       Impact factor: 14.307

10.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Authors:  E A Grimm; A Mazumder; H Z Zhang; S A Rosenberg
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.